Xinhua Pharma Wins China Trial Approval for Dual‑Mechanism PAH Drug LXH‑1211
Shandong Xinhua Pharmaceutical Co., Ltd. (HKG: 0719) announced that its pulmonary arterial hypertension (PAH) candidate...
Xinhua Pharmaceutical
Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer’s Disease
China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II...
Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma
Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton...
Phase I Success for Shandong Xinhua’s OAB-14, Advancing to Phase IIa in Alzheimer’s Therapy
Shandong Xinhua Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Shenzhen (SHE: 000756), has...
Xinhua Pharma’s OAB-14 Receives NMPA Approval for Phase I Alzheimer’s Study
China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) has announced receiving approval from the National...
Shandong Xinhua and Bayer Announce Strategic Partnership at CIIE
A strategic partnership between China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) and Bayer Consumer...
Shandong Xinhua Pharmaceutical Inks Tech Transfer Deal for LXH-2201 with IMM
China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) has signed a technology transfer agreement with...